Compare BW & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BW | GYRE |
|---|---|---|
| Founded | 1867 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 919.9M | 759.1M |
| IPO Year | N/A | 2004 |
| Metric | BW | GYRE |
|---|---|---|
| Price | $8.84 | $8.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $7.00 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 2.2M | 58.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 103.55 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | ★ $275,000.00 |
| Revenue This Year | N/A | $11.59 |
| Revenue Next Year | $6.69 | $26.31 |
| P/E Ratio | ★ N/A | $214.38 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.22 | $6.11 |
| 52 Week High | $11.57 | $13.47 |
| Indicator | BW | GYRE |
|---|---|---|
| Relative Strength Index (RSI) | 47.58 | 53.69 |
| Support Level | $7.98 | $6.94 |
| Resistance Level | $11.57 | $9.31 |
| Average True Range (ATR) | 0.76 | 0.37 |
| MACD | -0.17 | 0.03 |
| Stochastic Oscillator | 26.43 | 48.89 |
Babcock & Wilcox Enterprises Inc is a power generation equipment supplier and servicing company that operates in three segments: B&W Renewable, B&W Environmental, and B&W Thermal. B&W Thermal, focuses on steam generation products and solutions for plants in the power generation, oil, and gas, and industrial sectors, generates the majority of the company's revenue. B&W Renewable focuses on sustainable power and heat generation while B&W Environmental focuses on emissions control. The company's customer base spans the industrial, electrical utility, and municipal industries located predominantly in the United States, Canada, Denmark, the United Kingdom, and other regions. Business in the U.S. contributes the vast majority of its revenue.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.